Detection and Quantification of Drug-Protein Adducts in Human Liver

Overview

Journal J Proteome Res

Publisher American Chemical Society

Specialty Biochemistry

Date 2024 Oct 23

PMID 39442081

Authors

Alex Zelter

Michael Riffle

David D Shteynberg

Guo Zhong

Ellen B Riddle

Michael R Hoopmann

Daniel Jaschob

Robert L Moritz

Trisha N Davis

Michael J MacCoss

Nina Isoherranen

Affiliations

Soon will be listed here.

Abstract

Covalent protein adducts formed by drugs or their reactive metabolites are risk factors for adverse reactions, and inactivation of cytochrome P450 (CYP) enzymes. Characterization of drug-protein adducts is limited due to lack of methods identifying and quantifying covalent adducts in complex matrices. This study presents a workflow that combines data-dependent and data-independent acquisition (DDA and DIA) based liquid chromatography with tandem mass spectrometry (LC-MS/MS) to detect very low abundance adducts resulting from CYP mediated drug metabolism in human liver microsomes (HLMs). HLMs were incubated with raloxifene as a model compound and adducts were detected in 78 proteins, including CYP3A and CYP2C family enzymes. Experiments with recombinant CYP3A and CYP2C enzymes confirmed adduct formation in all CYPs tested, including CYPs not subject to time-dependent inhibition by raloxifene. These data suggest adducts can be benign. DIA analysis showed variable adduct abundance in many peptides between livers, but no concomitant decrease of unadducted peptides. This study sets a new standard for adduct detection in complex samples, offering insights into the human adductome resulting from reactive metabolite exposure. The methodology presented will aid mechanistic studies to identify, quantify and differentiate between adducts that result in adverse drug reactions and those that are benign.

References

Uetrecht J, Naisbitt D . Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013; 65(2):779-808. PMC: 3639727. DOI: 10.1124/pr.113.007450. View

Masubuchi N, Makino C, Murayama N . Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem Res Toxicol. 2007; 20(3):455-64. DOI: 10.1021/tx060234h. View

Chen Q, Ngui J, Doss G, Wang R, Cai X, Dininno F . Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol. 2002; 15(7):907-14. DOI: 10.1021/tx0200109. View

Baillie T . Targeted Covalent Inhibitors for Drug Design. Angew Chem Int Ed Engl. 2016; 55(43):13408-13421. DOI: 10.1002/anie.201601091. View

Lin A, Short T, Noble W, Keich U . Improving Peptide-Level Mass Spectrometry Analysis via Double Competition. J Proteome Res. 2022; 21(10):2412-2420. PMC: 10108709. DOI: 10.1021/acs.jproteome.2c00282. View

Evans D, Watt A, Nicoll-Griffith D, Baillie T . Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol. 2004; 17(1):3-16. DOI: 10.1021/tx034170b. View

Tsantilas K, Merrihew G, Robbins J, Johnson R, Park J, Plubell D . A Framework for Quality Control in Quantitative Proteomics. J Proteome Res. 2024; 23(10):4392-4408. DOI: 10.1021/acs.jproteome.4c00363. View

Orr S, Ripp S, Ballard T, Henderson J, Scott D, Obach R . Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem. 2012; 55(11):4896-933. DOI: 10.1021/jm300065h. View

Sharma V, Eckels J, Schilling B, Ludwig C, Jaffe J, MacCoss M . Panorama Public: A Public Repository for Quantitative Data Sets Processed in Skyline. Mol Cell Proteomics. 2018; 17(6):1239-1244. PMC: 5986241. DOI: 10.1074/mcp.RA117.000543. View

10.

Riffle M, Hoopmann M, Jaschob D, Zhong G, Moritz R, MacCoss M . Discovery and Visualization of Uncharacterized Drug-Protein Adducts Using Mass Spectrometry. Anal Chem. 2022; 94(8):3501-3509. PMC: 8892443. DOI: 10.1021/acs.analchem.1c04101. View

11.

Ariza A, Mayorga C, Fernandez T, Barbero N, Martin-Serrano A, Perez-Sala D . Hypersensitivity reactions to β-lactams: relevance of hapten-protein conjugates. J Investig Allergol Clin Immunol. 2015; 25(1):12-25. View

12.

Leeming M, Donald W, OHair R . Nontargeted Identification of Reactive Metabolite Protein Adducts. Anal Chem. 2017; 89(11):5748-5756. DOI: 10.1021/acs.analchem.6b04604. View

13.

Ahire D, Basit A, Karasu M, Prasad B . Ultrasensitive Quantification of Drug-metabolizing Enzymes and Transporters in Small Sample Volume by Microflow LC-MS/MS. J Pharm Sci. 2021; 110(7):2833-2840. PMC: 8772585. DOI: 10.1016/j.xphs.2021.03.020. View

14.

VandenBrink B, Davis J, Pearson J, Foti R, Wienkers L, Rock D . Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation. Mol Pharmacol. 2012; 82(5):835-42. DOI: 10.1124/mol.112.080739. View

15.

Gan J, Zhang H, Humphreys W . Drug-Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization. Chem Res Toxicol. 2016; 29(12):2040-2057. DOI: 10.1021/acs.chemrestox.6b00274. View

16.

Singh J . The Ascension of Targeted Covalent Inhibitors. J Med Chem. 2022; 65(8):5886-5901. DOI: 10.1021/acs.jmedchem.1c02134. View

17.

Chambers M, MacLean B, Burke R, Amodei D, Ruderman D, Neumann S . A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012; 30(10):918-20. PMC: 3471674. DOI: 10.1038/nbt.2377. View

18.

Geib T, Moghaddam G, Supinski A, Golizeh M, Sleno L . Protein Targets of Acetaminophen Covalent Binding in Rat and Mouse Liver Studied by LC-MS/MS. Front Chem. 2021; 9:736788. PMC: 8417805. DOI: 10.3389/fchem.2021.736788. View

19.

Park B, Boobis A, Clarke S, Goldring C, Jones D, Kenna J . Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov. 2011; 10(4):292-306. DOI: 10.1038/nrd3408. View

20.

Park B, Kitteringham N, Maggs J, Pirmohamed M, Williams D . The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol. 2005; 45:177-202. DOI: 10.1146/annurev.pharmtox.45.120403.100058. View